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Abstract: Objectives: (1.1) to evaluate the association between baseline 18F-FDG PET/CT
semi-quantitative parameters of the primary lesion with progression free survival (PFS), overall
survival (OS) and response to immunotherapy, in advanced non-small cell lung carcinoma (NSCLC)
patients eligible for immunotherapy; (1.2) to evaluate the application of radiomics analysis of the
primary lesion to identify features predictive of response to immunotherapy; (1.3) to evaluate if tumor
burden assessed by 18F-FDG PET/CT (N and M factors) is associated with PFS and OS. Materials and
Methods: we retrospectively analyzed clinical records of advanced NCSLC patients (stage IIIb/c or
stage IV) candidate to immunotherapy who performed 18F-FDG PET/CT before treatment to stage the
disease. Fifty-seven (57) patients were included in the analysis (F:M 17:40; median age = 69 years old).
Notably, 38/57 of patients had adenocarcinoma (AC), 10/57 squamous cell carcinoma (SCC) and 9/57
were not otherwise specified (NOS). Overall, 47.4% patients were stage IVA, 42.1% IVB and 8.8% IIIB.
Immunotherapy was performed as front-line therapy in 42/57 patients and as second line therapy after
chemotherapy platinum-based in 15/57. The median follow up after starting immunotherapy was
10 months (range: 1.5–68.6). Therapy response was assessed by RECIST 1.1 criteria (CT evaluation
every 4 cycles of therapy) in 48/57 patients or when not feasible by clinical and laboratory data
(fast disease progression or worsening of patient clinical condition in nine patients). Radiomics
analysis was performed by applying regions of interest (ROIs) of the primary tumor delineated
manually by two operators and semi-automatically applying a threshold at 40% of SUVmax. Results:
(1.1) metabolic tumor volume (MTV) (p = 0.028) and total lesion glycolysis (TLG) (p = 0.035) were
significantly associated with progressive vs. non-progressive disease status. Patients with higher
values of MTV and TLG had higher probability of disease progression, compared to those patients
presenting with lower values. SUVmax did not show correlation with PD status, PFS and OS. MTV
(p = 0.027) and TLG (p = 0.022) also resulted in being significantly different among PR, SD and PD
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groups, while SUVmax was confirmed to not be associated with response to therapy (p = 0.427).
(1.2) We observed the association of several radiomics features with PD status. Namely, patients
with high tumor volume, TLG and heterogeneity expressed by “skewness” and “kurtosis” had a
higher probability of failing immunotherapy. (1.3) M status at 18F-FDG PET/CT was significantly
associated with PFS (p = 0.002) and OS (p = 0.049). No significant associations were observed for N
status. Conclusions: 18F-FDG PET/CT performed before the start of immunotherapy might be an
important prognostic tool able to predict the disease progression and response to immunotherapy in
patients with advanced NSCLC, since MTV, TLG and radiomics features (volume and heterogeneity)
are associated with disease progression.
Keywords: PET/CT; immunotherapy; PD-1; PD-L1; response to therapy; NSCLC
1. Introduction
Lung cancer remains the leading cause of cancer-related death, despite continuous progresses
in diagnosis and therapy [1]. Non-small cell lung carcinoma (NSCLC) accounts for 80–85% of all
cases of lung cancer [1]. In almost half of the patients, the diagnosis of NSCLC is performed when
the disease is already in advanced stages (stage III or stage IV), having an estimated overall 5-year
survival rate of 18% [2]. In more than half of patients, the diagnosis of NSCLC is performed when
the disease is already in advanced stage with an estimated overall 5-year survival rate of 18% [2,3].
Platinum-based chemotherapy can improve outcome, but the rise of immunotherapy has changed
this scenario. Multiple molecules targeting the programmed cell death-1 (PD-1) and the programmed
death ligand-1 (PD-L1) axis have been proposed [3]. Different immune checkpoint inhibitors have been
approved in the second line setting on the basis of an improving in overall survival (OS) compared to
chemotherapy, irrespective to PDL1 expression or with a PD-L1 expression ≥1% for pembrolizumab.
Pembrolizumab has also been approved as first-line treatment for advanced NSCLC with PD-L1 higher
than 50%, given the significant increase in both progression free survival (PFS) (10.3 versus 6 months)
and OS (30 vs. 14.2 months) compared to chemotherapy [3,4]. Moreover, combination strategies of
chemo-immunotherapy have recently enriched the upfront therapy approach. However, the benefit
with immunotherapy is not seen for the entire population, making the identification of biomarkers and
predicting tools a critical step in selecting the ideal candidate population. In NSCLC adenocarcinoma,
platinum chemotherapy, plus pemetexered and pembrolizumab, reached a disease control rate of 84.6%,
while it was 70.4% for chemotherapy only [5]. However, approximately 15% of positive PD-L1 patients
will have disease progression within two months and a median survival of only three months [4].
The inter-patient, inter-tumour and even intra-tumour heterogeneity seem to be the major reasons of
such a large prognosis variability, representing a key challenge for the scientific community. In this
scenario, the application of new generation image analysis, such as radiomics, might provide further
and useful information [6].
Radiomics is an emerging field, defined as the high-throughput extraction of quantitative
features from medical images [6,7]. This approach provides high-dimensional data describing the
properties of shape and texture of tumors captured in different diagnostic procedures, including PET
imaging. The radiomics features are believed to contain information that reflects underlying tumor
pathophysiology and allow evaluation of tumor heterogeneity [6,7]. The primary goal of radiomics is to
build a clinically relevant predictive, descriptive, or prognostic model using these parameters. Focusing
on the relationship between quantitative biological features and cancer prognosis by non-invasive
method and aiding clinicians in selecting the appropriate treatments, radiomics is considered a step
toward the application of personalized medicine in routine practice. In this respect, NSCLC is a key
example to show the advantages of a tailored approach [8,9].
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2. Materials and Methods
2.1. Objectives
The objectives of this study were:
(1.1) to evaluate the association between 18F-FDG PET/CT baseline semi-quantitative parameters
of the primary lesion in advanced NSCLC patients eligible for immunotherapy with patient’s outcome
(PFS and OS) and response to immunotherapy,
(1.2) to evaluate the application of radiomics analysis of the primary lesion for texture analysis to
extract characteristics (quantitative biomarkers) from PET/CT images to represent tumor pathology or
heterogeneity (phenotype),
(1.3) to evaluate if tumor burden assessed by 18F-FDG PET/CT, as nodal (N) and metastatic (M)
status, is associated with PFS and OS.
2.2. Study Design and Inclusion Criteria
This is a retrospective, observational study approved by the ethical committee A.O.U. Città
della Salute e della Scienza di Torino (IRB number: 0011604; code: IMMUNO PET-19). We analyzed
the records and clinical/pathological characteristics of patients referred to Pulmonary Oncology
Department, San Luigi Gonzaga Hospital, University of Turin. Eligible patients matched all the
following inclusion criteria: (a) biopsy proven advanced NSCLC (stage IIIb/c or stage IV); (b) candidate
to immunotherapy targeting the PD-1 or PD-L1; (c) 18F-FDG PET/CT performed at baseline, during
the diagnostic work-up, within the start of immunotherapy. Patients with missing data and lost
follow-up were excluded from the analysis. Compliance with ethical standards: Ethical approval for
all procedures performed in studies involving human participants was in accordance with the ethical
standards of the institutional and/or national research committee and with the principles of the 1964
Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent
and local ethical committee approval: informed consent form (ICF) was obtained from all individual
participants enrolled in this retrospective analysis. ICF has been provided.
2.3. 18F-FDG PET/CT Image Acquisition and Interpretation
Here, 18F-FDG PET/CT were performed with a standard protocol. Patients were instructed to fast
for at least 6 h before the scan, and blood glucose levels were measured before the injection of 18F-FDG.
Patients were excluded if their blood glucose levels at the time of the scans exceeded 150 mg/dL.
Patient protocol included the intravenous injection of 2.5–3 MBq/kg of 18F-FDG, up to a maximum
of 370 MBq (10 mCi), followed by a 60-min uptake period. All patients underwent PET/CT scan in a
dedicated tomograph: AOU Città della Salute e della Scienza and IRCSS Istituto di Candiolo (Philips
Gemini Dual-slice EXP, Philips Medical Systems, Cleveland, OH, USA)); Affidea-IRMET (Discovery
610, GE Healthcare, Chicago, IL, USA). An attenuation-corrected whole-body scan (base of the skull to
mid thighs), 2 to 2.5 min per bed position (with an axial field-of-view of 18 cm per bed position), starting
60 min after tracer injection, was acquired. All patients performed a low-dose CT for attenuation
correction and anatomical correlation of PET findings. The tomographs results were validated for a
proper quantification and quality of the images recorded. The PET scans were reconstructed by ordered
subset expectation maximization (OSEM)-based algorithms. All PET/CT images were analyzed with
dedicated workstation (Advantage; GE Healthcare) and were independently interpreted with central
reading by two nuclear medicine physicians, aware of clinical data.
2.4. PET Semi-Quantitative Parameters and Radiomics Analysis
Semi-quantitative PET parameters and radiomics features of the primary lesion were extracted
using the open-access LIFEx platform v5.1 (IMIV/CEA, Orsay, France). For each primary lesion
were evaluated PET semi-quantitative parameters, including maximum standardized uptake value
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(SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG). The delineation of each
primary lung lesion was performed manually, slice-by-slice, independently by two expert operators.
Region of interest (ROI) with a threshold at 40% of SUVmax was also applied. MTV represents the
volume of the above given ROIs. 3D ROIs based on percentage of SUVmax were applied (3D isocontour
at 41% of the maximum pixel value [VOI41]). TLG was calculated as the product of the ROI average
SUVmean multiplied by the corresponding MTV. In the longitudinal setting, the quantitative metrics
described above were derived using the same approach for all PET/CT examinations in the same
patient. Radiomics features were extracted from each of the two ROIs. The following radiomics
features were analyzed: size and shape based–features such as volume, maximum diameter along
different orthogonal directions, maximum surface, tumor compactness, and sphericity; first-order
statistics features reporting the mean, median, maximum, minimum values of the voxel intensities on
the image, as well as their skewness (asymmetry), kurtosis (flatness), uniformity, and randomness
(entropy) and second-order statistics features include the so-called textural features. Lymph node and
systemic metastasis were evaluated and grouped as N and M status.
2.5. Evaluation of the Response to Immunotherapy
Therapy response was routinely assessed by CT evaluation every 4 cycles of therapy and
by clinical/laboratory evaluation. The diagnostic assessment of response to immunotherapy was
performed with response evaluation criteria in solid tumors (RECIST) 1.1 criteria. Complete response
(CR) was the disappearance of the primary tumor, partial response (PR) was a decrease of 30% or more
in the longest diameter of the primary tumor, progressive disease (PD) was an increase of 20% or more
in the longest diameter of the primary tumor, and stable disease (SD) was noted in patients whose
tumors did not show either sufficient shrinkage to qualify for PR or a sufficient increase to qualify
for PD [10,11]. When CT evaluation was not feasible for fast disease progression or the worsening of
patient clinical condition, the response to immunotherapy was performed by clinical and laboratory
evaluation only.
2.6. Outcome Measurements and Statistical Analysis
Demographic and baseline disease characteristics were recorded, censoring the times of observation
on July 2019, at a median follow-up of 10 months (IQR 6–14 months). The primary endpoint was PFS,
while the secondary one was OS. PFS was defined as the time from the start of immunotherapy to
progression/death for any cause. OS was defined as the time from the start of immunotherapy to death
as a result of any cause; patients still alive were censored at the date of last contact. The response to
immunotherapy was assessed considering both clinical follow-up and RECIST 1.1 criteria.
Patient characteristics were compared using the Fisher’s exact test for categorical variables and
the Mann–Whitney test for continuous ones. PFS and OS curves were estimated by the Kaplan–Meier
method, comparing the two arms by the log-rank test and calculating 95% CIs. All p-values were
obtained by 2-sided exact method at the conventional 5% significance level. All statistical analyses
were performed in R 3.6.1.
Considering the radiomics analysis, univariate analysis with Kruskal–Wallis test was performed
for each variable (histology, PDL-1 expression, disease stage, progression and response to
therapy). The intraclass correlation coefficient (ICC) was used to assess intra- (by observer 1)
and inter-observer (by observers 1 and 2) differences in texture and evaluate the reproducibility of
textural parameters. The ICC was also used to assess differences in texture between manual and
semi-automatic segmentation.
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3. Results
3.1. Population Characteristics
Fifty-seven patients have been retrospectively enrolled: 17 females and 40 males, with a median age
of 69 years old (range 39–84 years old). Three out of 57 patients were non-smokers, 33/57 were former
smokers, while 21/57 were current smokers. Sixty-six percent (38/57) of patients had adenocarcinoma
(AC), 17.5% (10/57) squamous cell carcinoma (SCC) and 15.7% (9/57) were not otherwise specified
(NOS). According to the 8th Edition of TNM in Lung Cancer (8), about half of the patients (47.4%)
were stage IVa, 42.1% were IVb and 8.8% of patients were IIIb. The Eastern Cooperative Oncology
Group, performance status (ECOG PS) was 0 in 20/57 patients, 1 in 35/57 and two patients had an
ECOG PS of 2. All patients were wildtype (no EGFR mutations, no ALK rearrangements detected).
The PD-L1 expression on the bioptic specimen was evaluated in 51/57 patients. Notably, 80.4% of
patients (41/51) presented a PD-L1 expression higher than 50%, 7.8% (4/51) between 1 and 49% and
11.8% (6/51) patients lower than 1%. All patients’ characteristics are listed in Table 1.
Table 1. Overall population (n = 57) characteristics.
Characteristics Value
Age Median 69 years old (range 39–84)
Sex
Male 40/57 (70.2%)
Female 17/57 (29.8%)
Smoking Status
Non-smoker 3/57 (5.3%)
Ex-smoker 33/57 (57.9%)
Current smoker 21/57 (36.8%)
Histological Variant
Adenocarcinoma 38/57 (66.6%)
Squamous cell carcinoma 10/57 (17.5%)
NOS 9/57 (15.7%)
ECOG PS
0 20/57 (35.1%)
1 35/57 (61.4%)
2 2/57 (3.5%)
Stage at Diagnosis
IB 1/57 (1.75%)
IIB 1/57 (1.75%)
IIIA 5/57 (8.8%)
IIIB 7/57 (12.3%)
IIIC 1/57 (1.7%)
IVA 26/57 (45.6%)
IVB 16/57 (28.1%)
Stage before IO
IIIB 6/57 (8.8%)
IVA 27/57 (47.4%)
IVB 24/57 (42.1%)
PD-L1 expression analysis
Not Performed 6/57 (10.5%)
<1% 6/57 (10.5%)
1–49% 4/57 (7.0%)
>50% 41/57 (72.0%)
Immunotherapy
First line IO 42/57 (73.7%)
Second line IO 15/57 (26.3%)
NOS: Not Otherwise Specified; ECOG PS: Eastern Cooperative Oncology Group Performance Status; IO:
Immuno-Oncology therapy.
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3.2. Immunotherapy Scheme
Treatment was decided by referent physicians considering tumor histology, PD-L1 expression and
patients’ risk factors. Immunotherapy was performed as a frontline therapy in 42/57 (73.7%) patients
and as a second line therapy after chemotherapy in 15/57 (26.3%) patients. The formers were all treated
with Pembrolizumab after the assessment of PD-L1 expression higher than 50%. The latter were treated
with Pembrolizumab in 5 cases, Nivolumab in 5 cases and Atezolizumab in 5 cases as well. Of these
15 cases treated with immunotherapy as second line, 8 patients received platinum + pemetrexed,
5 patients platinum + gemcitabine and 2 patients platinum + docetaxel. Six out of fifteen patients
underwent surgery on the primary lesion before starting immunotherapy. Pembrolizumab, nivolumab
and atezolizumab were administered intravenously at the standard dose.
3.3. Follow-Up and Therapy Response to Immunotherapy
The median follow-up was 10 months (range 1.5–68.6; IQR 6–14 months). Forty percent (23/57)
of patients died from cancer-related causes, while 59.6% (34/57) were alive with evidence of disease.
At the last follow-up, 30 patients were PD, 19 were SD and 8 were PR. No CR was observed. Thirty
patients (52.6%) experienced disease progression during therapy. Among patients with progressive
disease, 21 had the appearance of new lesions on CT performed as part of monitoring therapy response
(RECIST 1.1). In 9 cases, CT evaluation was not feasible (fast disease progression or worsening of
patient clinical condition) and disease progression was observed by clinical and laboratory evaluation.
Four patients experienced immunotherapy-induced toxicity (skin reaction, cough and rising liver
enzymes) and four patients experienced acute events (transient ischemic attack, pneumonia and acute
respiratory failure).
Immunotherapy was suspended in 30/57 patients. The causes of suspension were: progression
(clinical and/or radiological) of disease in 27 cases assessed through CT and/or clinical evaluation,
severe toxicity in 2 cases and death in 1 case. In 25/57 patients, immunotherapy was ongoing at the
time of the last follow-up. The median number of cycles of therapy was 7 (mean = 11; range 1–69).
3.4. 18F-FDG PET/CT Findings
First, 18F-FDG PET/CT was performed as routine diagnostic procedure to stage the disease before
the start of immunotherapy. The median time from PET/CT and the start of immunotherapy was 37
days (mean = 45; range 4–133 days). All primary tumors, observed in the 51/57 patients who did not
receive surgery and/or radiation therapy with radical intent, exhibited increased FDG uptake.
Twenty-two patients were N0, while 35/57 had positive lymph nodes (N+). In details, 10 were
N1 (ipsilateral peribronchial and/or hilar and intrapulmonary), 12 patients were N2 (ipsilateral
mediastinal and/or subcarinal nodes), and 13 patients were N3 (contralateral mediastinal or hilar
nodes or supraclavicular nodes). Systemic metastases were seen in 34/57 patients, while 23 patients
were staged as M0. 18F-FDG PET/CT observed adrenal metastases in 10 cases, contralateral lung
nodules in 9, bone metastases in 9, liver lesions in 6, pleural involvement or malignant effusion in 5,
extra-pulmonary lymph nodes in 2, soft tissue localization in 2 cases and 1 mesenterial nodule. Eleven
patients were classified as M1a (contralateral lung or pleural/pericardial nodule or effusion), six were
M1b (single extra-thoracic metastasis) and seventeen were M1c (multiple extra-thoracic metastases).
3.5. PET Semi-Quantitative Parameters Analysis (Objective 1.1)
The values of baseline 18F-FDG PET/CT semi-quantitative parameters of the primary lesion are
listed in Table 2. At the Mann–Whitney test, MTV (p = 0.028) and TLG (p = 0.035) were significantly
associated with progressive vs. non-progressive disease status (Table 3). Patients with higher values
of MTV and TLG of the primary lesion at the baseline PET/CT had higher probability of disease
progression, compared to those patients presenting with lower values. SUVmax values did not show
significant association between the two groups (PD vs. non-PD patients) (p= 0.55). In the Kaplan–Meier
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plot analysis, the variables resulted associated with PD vs. non-PD status (MTV and TLG) were
compared with PFS and OS (Figure 1). MTV and TLG were stratified according to the median value:
upper and lower median value (MTV = 74.1 ml3; TLG = 310.8). Kaplan–Meier curves showed a trend
to predict disease progression among patients with MTV and TLG lower or higher the median values.
However, the log rank test of the two curves showed them not to be significantly different (Figure 1).
In patients with MTV and TLG upper median values, PFS was 5 months, while OS was 15 months.
In patients with MTV and TLG lower median values, PFS and OS were not reached (minimum 50% of
events at last follow-up not reached).
Table 2. In this table; 18F-FDG PET/CT semi-quantitative parameters: SUVmax, metabolic tumor
volume (MTV) and total lesion glycolysis (TLG) values.
PET Parameters Minimum Percentile 25 Median Percentile 75 Maximum
SUVmax (g/mL) 1.4 5.8 9.5 13.5 30.5
MTV (mL3) 3.1 36.7 74.1 163.3 695.2
TLG 2.8 87.3 310.8 852.9 4639.8
Table 3. SUVmax, MTV and TLG values among patients with progressive (PD) and non-progressive
(non-PD) disease.
Associations Between Baseline PET Parameters and PD vs. non-PD
PET Parameters Status Minimum Percentile 25 Median Percentile 75 Maximum pValue
SUVmax (g/mL) PD 2.5 5.8 11.5 13.6 30.5 0.55non-PD 1.4 5.9 9.3 13.4 28.9
MTV (mL3)
PD 3.1 47.0 124.4 203.1 695.2
0.028non-PD 3.1 19.7 57.4 86.6 548.5
TLG
PD 4.5 165.9 536.1 988.1 2820.3
0.035non-PD 2.8 55.0 205.8 417.8 4639.8
In the Kruskal–Wallis test, MTV (p = 0.027) and TLG (p = 0.022) resulted in being significantly
different among PR, SD and PD groups (Table 4). SUVmax was confirmed to not be associated with
response to therapy criteria (p = 0.427) (Table 4).
Table 4. Association of MTV and TLG with response to immunotherapy, as assessed by response
evaluation criteria in solid tumors (RECIST) 1.1 criteria and clinical follow-up.
PET Parameters
Associations Between Baseline PET Parameters and Response to Immunotherapy
Status Minimum Percentile 25 Median Percentile 75 Maximum pValue
SUVmax (g/mL)
PR 1.4 5.8 8.8 13.2 15.3
0.427SD 5.7 9.2 11.9 15.0 28.9
PD 2.5 6.4 10.7 13.5 30.5
MTV (mL3)
PR 3.1 15.3 49.5 79.6 173.9
0.027SD 26.9 72.2 75.0 375.9 548.5
PD 3.1 44.3 124.3 202.6 695.2
TLG
PR 2.8 30.4 139.3 251.3 865.6
0.022SD 83.4 310.8 417.8 852.9 4639.8
PD 4.5 151.3 440.8 979.9 2820.3
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3.6. Radiomics Analysis (Objective 1.2)
The intraclass correlation coefficient (ICC) analysis of the texture parameters of the primary
lesion, based on two different delineations generated by two observers, showed that all parameters
presented good reproducibility (ICC > 0.95), except for GLZLM_SZLGE (ICC = 0.37). However,
when applying a semi-automatic segmentation (threshold = 40% of the SUVmax), only 8 features
showed good reproducibility (SUVmax, sphericity, two first-order statistics features and 4 textural
features. ICC > 0.95). The univariate analysis with the Kruskal–Wallis test was performed for the
following variables: histology, PDL-1 expression, disease stage, progression and response to therapy.
Histological variants: the only feature associated with different histological subtypes was SUVmax
(Figure 2). Namely, SCC showed higher SUVmax values than AC and NOS subtype.
PD-L1 expression: several features (including SUVmax, volume, busyness, coarseness,
GLZML_ZLNU and GLZML_GLNU) resulted in being significantly different between patients with
PD-L1 expression lower than 1%, between 1% and 49% and higher than 50%. Considering the
semi-automatic ROIs, only two features (coarseness and GLZLM_ZLNU) maintained the statistical
correlation (Figure 3).
Disease stage: radiomics features did not show significant difference between IIIb, IVa and IVb
patients at both manual and semi-automatic segmentation.
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volume, higher asymmetry and kurtosis had higher probability to progress.  
Figure 3. Box plots of radiomics features (coarseness and GLZLM_ZLNU) showing correlation with
PD-L1 expression.
Progression status: several features showed differences between PD vs. non-PD patients, such as
volume (p= 0.035), TLG (p= 0.037), three first-order histograms-based features (kurtosis, excess-kurtosis
and skewness) and six textural features (GLZLM_LZE, GLRLM_RP, GLRLM_SRE, GLRLM_HGRE,
GLRLM_SRHGE and GLCM Homogeneity) (Figure 4). GLZLM represents the grey-level zone length
matrix and provides information on the size of homogeneous zones for each grey-level in 3 dimensions.
GLZLM_LZE is the distribution of long homogeneous zones in an image. GLRLM represents the size
of homogeneous runs for each grey level. “Run” means the presence of elements in the image with the
same gray-level on in a row/line. GLCM_homogeneity considers the arrangements of pairs of voxels
to calculate textural indices and represents the homogeneity of grey-level voxel pairs.
Cancers 2020, 12, 1163 10 of 15
Cancers 2020, 12, x 10 of 15 
 
Figure 4. Box plots of radiomics features correlated with progressive (PD) vs. non-progressive disease 
status (non-PD). 
Response to therapy: TLG, volume and two textural features showed a significant difference 
between PR, SD and PD patients at both manual and semiautomatic evaluation. 
3.7. Tumor Burden Analysis (Objective 1.3) 
In the Kaplan–Meier plot analysis, M status (M0, M1a, M1b, M1c) as assessed by 18F-FDG 
PET/CT was significantly associated with PFS (p = 0.002) and OS (p = 0.049). Namely, patients with 
no visible metastases at PET/CT had significantly better outcome compared with those patients 
presenting with FDG avid metastases. No significant associations were observed for N status (N0, 
N1, N2, N3) as assessed by 18F-FDG PET/CT and PFS or OS. (Figure 5). 
Figure 4. Box plots of radiomics features correlated with progressive (PD) vs. non-progressive disease
status (non-PD).
Accordingly, patients with primary lung tumor presenting with higher TLG value, higher volume,
higher asymmetry and kurtosis had higher probability to progress.
Response to therapy: TLG, volume and two textural features showed a significant difference
between PR, SD and PD patients at both manual and semiautomatic evaluation.
3.7. Tumor Burden A alysis (Objective 1.3)
In the Kaplan–Meier plot analysis, M status (M0, M1a, M1b, M1c) as assessed by 18F-FDG PET/CT
was significantly associated with PFS (p = 0.002) and OS (p = 0.049). Namely, patients with no visible
metastases at PET/CT had significantly better outcome compared with those patients presenting with
FDG avid metastases. No significant associations were observed for N status (N0, N1, N2, N3) as
assessed by 18F-FDG PET/CT and PFS or OS. (Figure 5).
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4. Discussion
Over the past decade 18F-FDG PET/CT demonstrated to be a powerful tool for staging and assessing
treatment response in patients suffering from NSCLC [12,13]. Even if PET/CT is widely used in this
clinical scenario, limited data are currently available regarding the role of PET/CT semi-quantitative
parameters as predictors of patient outcome [14,15]. Findings are generally heterogeneous and this
variability might be probably related to the heterogeneity of the population enrolled. Furthermore,
the association of semi-quantitative parameters with patients’ outcome can be related to the clinical
stage of the disease (locally vs. advanced disease) and to the therapy investigated (chemo-radiotherapy
vs. biological therapy) [14–17]. At present, SUV values, MTV and TLG are the PET-derived parameters
used to assess the tumor metabolic activity in NSCLC [17]. MTV and TLG can easily be calculated in the
primary tumor by means of a segmentation technique. The manual or semi-automatic measurement of
the pre-treatment MTV has been shown to be better than SUVmax for predicting patients’ prognosis in
different solid neoplasms such as head and neck cancer, with or without metastases [18,19].
Our study aimed to investigate the relationship between the functional tumor parameters at
baseline (SUVmax, MTV, and TLG) and PFS and OS in patients with advanced NSCLC, presenting
with stage IIIB, IIIC, IVa and IVb, for whom immunotherapy was shortly planned. A significant
association of MTV and TLG of the primary lesions with PD was observed, since lower MTV and TLG
values were associated with non-PD status; while, on the contrary, primary lesions presenting with
higher values were more likely associated with the progression of the disease during immunotherapy.
On the contrary, SUVmax did not show significant association with both PFS and OS. These results are
in accordance with recent studies, suggesting a superior correlation of volumetric 18F-FDG PET/CT
parameters, rather than SUVmax only [7,9,20,21]. However, despite the fact that in the Kaplan–Meier
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analysis, MTV and TLG showed a trend in predicting disease progression, the curves associated with
PFS and OS were not statistically significant. This is probably due to the relatively small sample size
and the limited number of events that occurred.
Grizzi et al., in a preliminary analysis on 27 patients with NSCLC, found an antithetical correlation
between 18F-FDG PET/CT pre-treatment parameters and the response to immunotherapy. Authors
observed a rapid progression of disease after 8 weeks from the start of immunotherapy in patients with
a SUVmax up to 17.1 and a SUVmean up to 8.3, with a sensitivity of 88.9% and 100%, respectively [22].
Similarly, Evangelista et al. investigated the role of semi-quantitative 18F-FDG PET/CT parameters
in NSCLC treated with Nivolumab. Authors observed an association between the sum of metabolic
parameters of all lesions and PD status, with SUVmax having the strongest association [23]. Their data
seem to be in contrast with our analysis. However, authors considered all the lesions together as the
cumulative sum of all FDG deposits detected by PET/CT, while we specifically designed our study to
analyze semi-quantitative parameters of the primary lesion only, and we analyzed the correlation of
the tumor burden (N and M status assessed by 18F-FDG PET/CT) separately, with a dedicated objective
(objective 1.3). In our study, MTV and TLG were also significantly associated with immunotherapy
response. Patients with SD or PR had lower values of MTV and TLG compared to patients with PD.
No correlation was observed again between SUVmax values and response to therapy. Accordingly,
since MTV and TLG are parameters that accurately reflect the glycolytic metabolic status of a lesion and
thus the disease aggressiveness, 18F-FDG PET/CT might be considered as a prognostic tool to stratify
patients presenting with higher metabolic primary tumors that, most likely, will fail immunotherapy.
In our study, we also observed a significant association between the M status at 18F-FDG PET/CT
and PFS and OS. It is worth noting that 18F-FDG PET/CT offers the possibility of having a single-step
whole body examination that can clearly identify distant metastases and select NSCLC patients treated
with immunotherapy with a higher probability of experiencing rapid disease progression and poor
survival outcomes.
Immunotherapy has completely changed the prognosis and the care of patients with NSCLC.
However, the benefit with immunotherapy is not seen for the entire population, making the identification
of biomarkers a critical step in selecting the candidate population. Therefore, radiomics aims to identify
biomarkers that better predict patient response [24,25]. Radiomics has been investigated in various
studies to identify clinical and computational image-based predictors of rapid disease progression
phenotypes in NSCLC patients [7,26,27]. However, there are only few studies investigating the
application of this new field in patients with NSCLC treated with checkpoint-based immunotherapy
and most of them based radiomics analysis on CT images and enrolled heterogeneous population with
different primaries (e.g., lung and melanoma) [28,29]. Recently, Mu et al. presented promising data
and a novel methodological approach on the application of radiomics analysis in NSCLC treated with
immune checkpoint blockades. In their study, authors tested the hypothesis that radiomics features
from baseline pretreatment 18F-FDG PET/CT scans can predict the clinical outcomes of NSCLC patients
treated with checkpoint blockade immunotherapy. Among other findings, authors reported that when
investigating the informative components of multi-parametric radiomics signature (mp-RS) formula,
they found that multiple texture features (PET_SRLGE, KLD_SZE) positively correlated, suggesting
that the more heterogeneous tumors had a larger probability to have a durable clinical benefit (DCB).
These results are slightly in contrast with prior studies, which showed that more heterogeneous tumors
with CT textures had worse response to radiation or chemotherapy [30]. Our results were slightly
in contrast with Mu et al. [7] as well. In our study, the most interesting difference of features was
seen between patients with PD and patients with non-PD. Namely, patients with primary lung tumor
presenting with high TLG value, high volume and tumor heterogeneity represented by asymmetry
(skewness feature) and kurtosis (how heavily the tails of a distribution differ from the tails of a
normal distribution) had a higher probability of progression and were associated with non-response to
immunotherapy. However, differences in features extraction methodology and different endpoints
(DCB vs. PD) make these findings not completely comparable. Finally, segmentation is currently the
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rate-limiting step in radiomics analysis. To overcome this issue, in our study, the segmentation of the
ROIs was performed manually by two independent operators and semi-automatically, applying a
threshold of 40% of the SUVmax.
Limitation
This work is not exempt from limitations. The retrospective design of this analysis might have
probably affected population selection. A prospective design would probably offer the chance to recruit
a more homogenous population (e.g., same immunotherapy scheme, shorter range for PET scan before
immunotherapy, immunotherapy administrated as first-line). Namely, in our cohort, 26.3% of patients
received immunotherapy after platinum-based chemotherapy. However, the population enrolled
represents the typical cohort of patients generally referred to 18F-FDG PET/CT before immunotherapy
in daily clinical practice.
This analysis was performed in a relatively small sample size. A larger cohort would be preferable.
In our study, we observed an association of MTV and TLG with PD vs. non-PD status. Nevertheless,
this association was not maintained in the Kaplan–Meier analysis and, despite a non-negligible trend,
MTV and TLG were not statistically significantly associated with PFS. The limited number of events at
the end of follow-up, namely for patients with lower than median values for MTV and TLG, influenced
the correlation between these metabolic parameters and PFS and OS. It is probable that our statistical
model might rich significance in a larger cohort.
Another limitation is related to the lack of “early intermediate” PET performed while
immunotherapy was still on-going, in order to evaluate PET response to therapy. However, since the
role of PET imaging during immunotherapy is not yet established, 18F-FDG PET/CT is generally
performed in clinical practice at baseline only. Thus, none of the patients enrolled in our study
performed a second PET scan.
Considering radiomics analysis, the ideal setting would require a robust validation regarding
reconstruction and segmentation on different tomographs. In our analysis, despite similar 18F-FDG
PET/CT protocols and using the same reconstruction algorithm, the texture analysis was performed on
images derived by three different tomographs. A common issue with radiomics analysis is represented
by segmentation process (manual vs. automatic) and a comparison between the two approaches would
be preferable. However, to strengthen our analysis, we included two operators who independently
perform the segmentation. Furthermore, a threshold of 40% of SUVmax was also applied to both
operators’ ROI. Finally, in our study, segmentation was performed on PET images only, while low-dose
CT images were not segmented, and so not considered in our radiomics analysis.
5. Conclusions
According to our results, baseline 18F-FDG PET/CT performed before the start of immunotherapy
might be important, since it offers the chance to evaluate different quantitative parameters potentially
associated with different response to therapy in patients with advanced NSCLC. In our study,
and considering the limitations exposed above, MTV, TLG and radiomics features (volume and
heterogeneity) were associated with disease progression, while metastatic tumor stages assessed with
PET/CT were associated with different patients’ outcome.
These results, while far from definitive evidence, encouraged us to initiate a prospective trial
to investigate the role of radiomics features extracted from 18F-FDG PET/CT in NSCLC eligible
to immunotherapy.
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